NSCLC Stage IV

Oncology
4
Pipeline Programs
5
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
133%
Monoclonal Antibody
133%
ADC
133%
+ 2 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
N-803Phase 31 trial
Active Trials
NCT06745908Recruiting460Est. Jan 2029
Verona Pharma
Verona PharmaUK - London
1 program
1
Nivolumab and IpilimumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05597800Not Yet Recruiting105Est. Mar 2027
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
Sacituzumab Govitecan-Hziy 180 MG plus bevacizumabPhase 2ADC1 trial
Active Trials
NCT06401824Recruiting25Est. Apr 2027
Bristol Myers Squibb
1 program
1
Nivolumab Combined with AnlotinibPhase 1/2Small Molecule1 trial
Active Trials
NCT04507906Completed21Est. Mar 2022
QT
Q TherapeuticsUT - Salt Lake City
1 program
Oligo FucoidanN/A1 trial
Active Trials
NCT03130829WithdrawnEst. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
ImmunityBioN-803
Gilead SciencesSacituzumab Govitecan-Hziy 180 MG plus bevacizumab
Verona PharmaNivolumab and Ipilimumab
Bristol Myers SquibbNivolumab Combined with Anlotinib
Q TherapeuticsOligo Fucoidan

Clinical Trials (5)

Total enrollment: 611 patients across 5 trials

NCT06745908ImmunityBioN-803

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

Start: Oct 2025Est. completion: Jan 2029460 patients
Phase 3Recruiting
NCT06401824Gilead SciencesSacituzumab Govitecan-Hziy 180 MG plus bevacizumab

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Start: Apr 2025Est. completion: Apr 202725 patients
Phase 2Recruiting
NCT05597800Verona PharmaNivolumab and Ipilimumab

Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome

Start: Feb 2023Est. completion: Mar 2027105 patients
Phase 2Not Yet Recruiting
NCT04507906Bristol Myers SquibbNivolumab Combined with Anlotinib

Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC

Start: Nov 2020Est. completion: Mar 202221 patients
Phase 1/2Completed
NCT03130829Q TherapeuticsOligo Fucoidan

To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

Start: Apr 2017Est. completion: Apr 2020
N/AWithdrawn

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Senior Director of Clinical Operations

Arvinas
Remote
1h ago

Specialist, Quality Assurance

Umoja Biopharma
Louisville, Colorado, United States
3h ago
$85K - $105K/yr

Senior Facilities Technician

Umoja Biopharma
Louisville, Colorado, United States
3h ago

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
7h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
8h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 611 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)